Blood Building Peptide is for rapidly increasing RBC & Hemoglobin in Race Horses & Camels.

Blood Building Peptide is an erythropoiesis-stimulating agent (ESA) that is being tested in clinical trials for the treatment of anemia associated with chronic renal failure (CRF). Trials are evaluating the ability of this peptide to correct anemia by raising and maintaining hemoglobin (Hgb) levels within a target of 10-12 or 11-12 g/dL, depending on the situation.

In contrast to the current standard of care, recombinant protein-based ESAs, Blood Building Peptide is a novel, synthetic peptide-based ESA that is immunologically distinct from endogenous human erythropoietin (EPO), a protein produced by the kidneys to stimulate the production of oxygen-transporting red blood cells. The most advanced portion of Blood Building Peptide clinical development program is an ongoing Phase 3 program that consists of four studies (two in dialysis, two in non-dialysis) involving approximately 2,600 patients across almost 400 clinical sites in U.S. and Europe. These and other well-designed studies in patients with CRF will not only evaluate Blood Building Peptide ability to manage patients' Hgb with monthly dosing, but also the ability of Blood Building Peptide to maintain patients' Hgb between the range of 11 to 12 g/dL in non-dialysis patients and 10-12 g/dL in dialysis patients.

While the development of pure red cell aplasia (PRCA) is listed as a potential adverse reaction to currently approved ESAs, Phase 2 Blood Building Peptide data have shown that Blood Building Peptide has the potential to increase and maintain Hgb levels in patients who have developed PRCA as a result of ESA use. PRCA is a rare condition in which the body develops neutralizing antibodies to recombinant ESAs that negate the effects of the ESA as well as the body's naturally produced EPO. PRCA often leaves patients severely anemic and reliant on regularly administered blood transfusions and/or immunosuppressant therapy.

Actions - Increases red blood cells and Hgb

Indications - Horses with low blood count or anemia.

Form - Injectable/ Injection

Category - Blood Builders

For - Horses & Camels

Dosage and Administration
Adult Horses: 20 ml by intravenous injection, four consecutive days not closer than 2 days to race, preferably start using 7 days prior to event for 4 consecutive days.

Presentation - 80 ml sterile multi-dose glass vial.

Storage- Store below 25° C (Air Conditioning). Protect from light. Shelf life 12 months. Use the contents of the vial within 3 months of initial broaching, and discard any unused portion.

Warnings - Precautions : Do not give intramuscular under any circumstance. Do not use two weeks consecutive